Effect of Meglitinides on Postprandial Ghrelin Secretion Pattern in Type 2 Diabetes Mellitus

Rudovich, Natalia; Möhlig, Matthias; Otto, Bärbel; Pivovarova, O.; Spranger, Joachim; Weickert, Martin O.; Pfeiffer, Andreas F. H.

doi:10.1089/dia.2009.0129

Cited by 7 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a recent study found that treatment with repaglinide and nateglinide reconstructed postprandial ghrelin secretion patterns in diabetes, and thus nateglinide may help to improve the control of feeding behavior in patients with T2DM. 28 A few limitations to our study design should be considered when interpreting our results. In particular, the study population was relatively small, and the observation time was…”

Section: Discussionmentioning

confidence: 97%

Nateglinide and Acarbose Are Comparably Effective Reducers of Postprandial Glycemic Excursions in Chinese Antihyperglycemic Agent–Naive Subjects with Type 2 Diabetes

Zhou

Zhang

et al. 2013

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Background: Recent studies have identified postprandial glycemic excursions as risk factors for diabetes complications. This study aimed to compare the effects of nateglinide and acarbose treatments on postprandial glycemic excursions in Chinese subjects with type 2 diabetes. Subjects and Methods: This was a multicenter, open-label, randomized, active-controlled, parallel-group study. One hundred three antihyperglycemic agent-naive subjects with type 2 diabetes (hemoglobin A1c range, 6.5-9.0%) were prospectively recruited from four hospitals in China. The intervention was nateglinide (120 mg three times a day) or acarbose (50 mg three times a day) therapy for 2 weeks. A continuous glucose monitoring system was used to calculate the incremental area under the curve of postprandial blood glucose (AUC pp ), the incremental glucose peak (IGP), mean amplitude of glycemic excursions, SD of blood glucose, the mean of daily differences, and 24-h mean blood glucose (MBG). Subjects' serum glycated albumin and the plasma insulin levels were also analyzed. Results: Both agents caused significant reductions on AUC pp and IGP. Similarly, both treatment groups showed significant improvements in the intra-and interday glycemic excursions, as well as the 24-h MBG and serum glycated albumin compared with baseline (P < 0.001). However, neither of the agents produced a significantly better effect (P > 0.05). Moreover, the nateglinide-treated group had significantly increased insulin levels at 30 min and at 120 min after a standard meal compared with baseline, whereas the acarbose-treated group decreased. No serious adverse events occurred in either group. The rates of hypoglycemic episodes were comparable in the two groups, and no severe hypoglycemic episode occurred in either group. Conclusions: Nateglinide and acarbose were comparably effective in reducing postprandial glycemic excursions in antihyperglycemic agent-naive Chinese patients with type 2 diabetes, possibly through different pathophysiological mechanisms.

show abstract

Section: Discussionmentioning

confidence: 97%

Nateglinide and Acarbose Are Comparably Effective Reducers of Postprandial Glycemic Excursions in Chinese Antihyperglycemic Agent–Naive Subjects with Type 2 Diabetes

Zhou

Zhang

et al. 2013

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…The mealinduced decrease of ghrelin levels is impaired in type 2 diabetic subjects [20], suggesting that the impaired suppression of circulating ghrelin during the meal intake may partly account for the glucose intolerance as well as ongoing weight gain in type 2 diabetes. When wild-type and ghrelin-KO mice were fed a high-fat diet (HFD), both mouse lines developed moderate increases in body weight to a similar extent [8].…”

Section: Ghrelin As a Potential Therapeutic Target For Type 2 Diabetesmentioning

confidence: 99%

Ghrelin Function in Insulin Release and Glucose Metabolism

Dezaki

2013

Endocrine Development

View full text Add to dashboard Cite

Given its wide spectrum of biological activities such as growth hormone (GH) release, feeding stimulation, adiposity and cardiovascular actions, the discovery of ghrelin opened many new perspectives within neuroendocrine, metabolic and cardiovascular research, thus suggesting its possible clinical application. Circulating ghrelin is produced predominantly in the stomach, and its receptor GH secretagogue receptor (GHS-R) is expressed in a variety of central and peripheral tissues. Ghrelin, GHS-R and ghrelin O-acyltransferase (GOAT), the enzyme that promotes the acylation of the third serine residue of ghrelin, are all expressed in pancreatic islets, and this peptide is released into pancreatic microcirculations. Ghrelin inhibits insulin release in mice, rats and humans. The signal transduction mechanisms of ghrelin receptor in islet β-cells are very unique, being distinct from those utilized for GH release. Pharmacological and genetic blockade of islet-derived ghrelin markedly augments glucose-induced insulin release in vitro. Ablation of ghrelin, GHS-R or GOAT enhances insulin release and prevents impaired glucose tolerance in high-fat, diet-induced and leptin-deficient obese models. Thus, manipulation of the insulinostatic function of the ghrelin-GHS-R system, particularly that in islets, could optimize the amount of insulin release to meet the systemic demand. Ghrelin antagonism provides a novel strategy to treat type 2 diabetes with dysregulated insulin release.

show abstract

Current literature in diabetes

2010

Diabetes Metabolism Res

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of diabetes/metabolism. Each bibliography is divided into 26 sections: 1 Reviews; 2 General; 3 Genetics; 4 Epidemiology; 5 Immunology; 6 Obesity; 7 Prediction and Prevention; 8 Intervention: a) General; b) Care; c) Drug Therapy; d)Economics; e) Gene therapy; f) Nursing; g) Nutrition; h) Surgery; i) Transplantation; 9 Pathology and Complications: a) General; b) Cardiovascular; c) Eye disease; d) Gestational and fetal; e) Neurological; f) Podiatrical; g) Renal; 10 Endocrinology & Metabolism; 11 Experimental Studies; 12 Diagnosis and Techniques. Within each section, articles are listed in alphabetical order with respect to author

show abstract

Effect of Meglitinides on Postprandial Ghrelin Secretion Pattern in Type 2 Diabetes Mellitus

Abstract: Treatment with meglitinides reconstructed postprandial ghrelin secretion patterns to those of controls without diabetes. This observation may help to improve the control of feeding behavior in patients with T2DM.

Cited by 7 publications

References 51 publications

Nateglinide and Acarbose Are Comparably Effective Reducers of Postprandial Glycemic Excursions in Chinese Antihyperglycemic Agent–Naive Subjects with Type 2 Diabetes

Nateglinide and Acarbose Are Comparably Effective Reducers of Postprandial Glycemic Excursions in Chinese Antihyperglycemic Agent–Naive Subjects with Type 2 Diabetes

Ghrelin Function in Insulin Release and Glucose Metabolism

Current literature in diabetes

Contact Info

Product

Resources

About